Exact Sciences CEO Sees Steady Uptick in Cologuard Orders

The transcript discusses the positive reception and validation of a cancer screening test, Cologuard, by major institutions like the Mayo Clinic and FDA. Despite some critics, the company reports significant revenue growth and is focused on engaging more physicians and educating the public. The transcript also addresses concerns about scalability and refutes claims that doctors are not ordering more tests, highlighting a steady increase in orders.

Which major institutions have supported the Cologuard test?

• Johns Hopkins and CMS

• World Health Organization and NIH

• Harvard University and CDC

• Mayo Clinic and FDA

What is the company's main strategy to achieve profitability?

• Reducing the cost of the test

• Expanding the number of physicians ordering the test

• Increasing the price of the test

• Cutting down on marketing expenses

How many primary care physicians does the company believe will eventually order Cologuard?

• 300,000

• 200,000

• 100,000

• 50,000

What is the main reason for the increase in Cologuard test orders by doctors?

• Doctors receive a commission for each test ordered

• The test is easy to use and included in major guidelines

• The test is now free for all patients

• The test results are available instantly

What has been the trend in the number of doctors ordering Cologuard?

• A steady increase

• No change

• A steady decline

• A rapid decline